The stream · Daily digest
The stream: Tuesday, October 6, 2026
11 briefs from the Federal Register and ClinicalTrials.gov, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Regulation · 6
-
FDA requests public comments on ibogaine trial design
FDA is opening a docket to receive comments on design elements for early-phase trials of ibogaine drug products, with a deadline of November 20, 2026. The request follows guidance issued July 14, 2026 and seeks input on dose selection, safety monitoring, eligibility criteria and other protocol elements.
Source: Federal Register notice, October 6, 2026
-
FDA issues priority review voucher for FAYUVI (rebisufligene etisparvovec-hopf)
The FDA announced that it has awarded a priority review voucher to the sponsor of FAYUVI, a gene therapy approved on September 17, 2026. The voucher is granted to Ultragenyx Pharmaceutical Inc. for this rare pediatric disease product that meets the criteria under the FD&C Act.
Source: Federal Register notice, October 6, 2026
-
FDA determines pralidoxime chloride AUTOINJECTOR not withdrawn for safety or effectiveness
FDA has determined that pralidoxime chloride AUTOINJECTOR solution, 600 mg/2 mL (300 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination allows FDA to approve abbreviated new drug applications for the product if other requirements are met.
Source: Federal Register notice, October 6, 2026
-
FDA classifies focused ultrasound system as class II
The Food and Drug Administration issued a final order classifying the focused ultrasound system for non-thermal, mechanical tissue ablation into class II with special controls, effective October 6, 2026. The order codifies the classification in 21 CFR 878.4405 and identifies the special controls that will provide reasonable assurance of safety and effectiveness.
Source: Federal Register rule, October 6, 2026
-
FDA finalizes class II status for hyperoxia monitoring device adjunct to pulse oximetry
The FDA issued a final order on October 6, 2026, classifying the hyperoxia monitoring device adjunct to pulse oximetry into class II with special controls. The order, effective October 6, 2026, codifies the classification that was first applied on October 12, 2023.
Source: Federal Register rule, October 6, 2026
-
FDA finalizes exemption for certain class II clinical toxicology test systems
The FDA issued a final order exempting specific class II clinical toxicology test systems from premarket notification (510(k)) requirements, effective October 6, 2026. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations.
Source: Federal Register rule, October 6, 2026
Clinical trials · 5
-
Pharmazz, Inc. registers Phase 3 study of sovateltide for acute traumatic brain injury
The study, titled RESTORE-TBI, plans to enroll 214 participants and is scheduled to begin in December 2026. It is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial evaluating the efficacy and safety of sovateltide (IRL-1620) in patients with traumatic brain injury.
Source: ClinicalTrials.gov registry record, October 6, 2026
-
GlaxoSmithKline registers Phase 3 linerixibat safety eXtension study in Japan
The study plans to enroll 40 participants and start on October 9, 2026. It aims to assess the long-term safety of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and efficacy study, LLSAT (NCT04167358).
Source: ClinicalTrials.gov registry record, October 6, 2026
-
GlaxoSmithKline posts results of Phase 3 salbutamol safety study
Results for this study were first posted on ClinicalTrials.gov on October 6, 2026, for a Phase 3 trial that enrolled 471 participants. The study began May 31, 2024 and completed primary data collection on September 2, 2025.
Source: ClinicalTrials.gov results record, October 6, 2026
-
Janssen posts results of Phase 3 aticaprant study in major depressive disorder
Results for the VENTURA-LT study of aticaprant (JNJ-67953964) were first posted on October 6, 2026. The open-label, long-term safety and efficacy study enrolled 871 participants, started on September 22, 2022, and completed primary data collection on April 25, 2025.
Source: ClinicalTrials.gov results record, October 6, 2026
-
Vascular Therapies posts results of Phase 3 ACCESS 2 trial of Sirogen in ESRD patients
The ACCESS 2 trial, a Phase 3 study with 136 participants, evaluated the Sirolimus eluting Collagen implant (Sirogen) in patients undergoing arteriovenous fistula surgery. Results were first posted on ClinicalTrials.gov on October 6, 2026, after the study's primary completion on March 18, 2025.
Source: ClinicalTrials.gov results record, October 6, 2026